PATENT CLAIM ANALYSIS

Application Number: 16028160
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "055000"]

Abstract:
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

Claim (Index 11):
A method of photophysically destroying a neoplasm and concurrently generating an in situ autologous vaccine in a tumor-bearing host, the method comprising:\n (a) irradiating the neoplasm with a laser of a wavelength in the visible, near-infrared or infrared range, at a power and for a duration sufficient to produce a photothermal reaction inducing neoplastic cellular destruction and generating fragmented neoplastic tissue and cellular molecules; (b) forming the in situ vaccine by introducing an immunoadjuvant into the neoplasm by intratumor injection wherein the in situ vaccine comprises an amalgam of the fragmented tissue and cellular molecules and the immunoadjuvant, the immunoadjuvant being a viscoelastic glycated chitosan formulation of filter sterilized glycated chitosan polymer and a substantially aqueous solution, the glycated chitosan polymer having a molecular weight between about 50,000 Daltons to about 1,500,000 Daltons, the glycated chitosan polymer having glycated amino groups present from about one tenth of one percent to about thirty percent of available amino groups, the degree of deacetylation of a chitosan parent of the viscoelastic glycated chitosan is about 80%, wherein the substantially aqueous solution having a pH from between about 5 to about 7, wherein about one percent by weight of the glycated chitosan polymer is dissolved in the substantially aqueous solution, and wherein the aqueous solution has a viscosity from about one centistokes to about one hundred centistokes measured at about 25 degrees Celsius; and (c) stimulating the self-immunological defense system against neoplastic cellular multiplication by having the vaccine presented locally to induce an anti-tumor response systemically within the host.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.36364
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13037171', '13755105', '13258722', '10870342', '11818997']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7181265556116493
- 35 USC 102 Novelty (BERT): 0.4789103131985627
- Combined Prediction Score: 0.6942049313703407
- Mean Citation Score: 155.62205
- Max Citation Score: 195.53748
- Similarity Product: 150.826663158381

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test